

**Anti-Spike RBD Reference Antibody (Cilgavimab)
Recombinant Antibody
Catalog # APR10006****Specification**

Anti-Spike RBD Reference Antibody (Cilgavimab) - Product Information

Application	FC, Kinetics, Animal Model
Primary Accession	NA
Reactivity	Influenza A virus
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	148.82 KDa

Anti-Spike RBD Reference Antibody (Cilgavimab) - Additional Information**Target/Specificity**

Spike RBD

Endotoxin

< 0.001EU/ µg,determined by LAL method.

Conjugation

Unconjugated

Expression system

CHO Cell

Format


Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Anti-Spike RBD Reference Antibody (Cilgavimab) - Protein Information**Anti-Spike RBD Reference Antibody (Cilgavimab) - Protocols**


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


Anti-Spike RBD Reference Antibody (Cilgavimab) - Images



Anti-Spike RBD Reference Antibody (Cilgavimab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-Spike RBD Reference Antibody (Cilgavimab) is more than 99.35%, determined by SEC-HPLC.



Immobilized 2019nCoV RBD His at 2 $\mu\text{g/mL}$ can bind Anti-Spike RBD Reference Antibody (Cilgavimab) $\text{EC}_{50}=0.01122 \mu\text{g/mL}$.